Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2024 | $5.00 | Buy | ROTH MKM |
| 7/12/2022 | $6.00 | Buy | Aegis Capital |
| 6/23/2022 | $6.00 | Buy | B. Riley Securities |
| 1/5/2022 | $11.00 | Buy | Craig-Hallum |
| 1/5/2022 | $13.00 | Buy | Loop Capital |
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world's first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey. "We're excited to be the first to demonstrate the value of robotic high-density mapping and to offer this important innovation to our patients," said Dr. Corbisiero, Chief of Electrophysiology at
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. H.C. Wainwright 27th Annual Global Investment ConferenceMr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings. Lake Street Capital 9th Annual Best Ideas Growth ConferenceMr. Fischel will be available for one-on-one meetings on Thursday, September 11, 2025.
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
424B5 - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
10-Q - Stereotaxis, Inc. (0001289340) (Filer)
ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00
Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2025 financial results conference call When:Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (Interna
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)